62Cu-Diacetyl-Bis (N4-Methylthiosemicarbazone) PET in Human Gliomas: Comparative Study with [18F]Fluorodeoxyglucose and L-Methyl-[11C]Methionine PET

Abstract

BACKGROUND AND PURPOSE:

Discrimination between primary low-grade and high-grade glioma with 11C-methionine PET: a bivariate diagnostic test accuracy meta-analysis

“…Further, the heterogeneity of sensitivities from the main analysis (n = 13 studies) were lost in this subgroup analysis indicating more homogenous results across studies. Loss of heterogeneity was also found in the subgroup of studies with high quality adherence according to STARD, 10,29,30,35,38 and for studies reporting on MET uptake ratio [28][29][30][31]34,36,37 rather than SUV 10,15,32,33,35,38 ratio. The subgroup of studies reporting on SUV ratio had an AUC of 0.83 compared to uptake ratio with AUC 0.78.…”

“…The following covariates were evaluated for a moderating effect on the diagnostic potential to discriminate between LGG and HGG by MET PET in bivariate meta-regression; bias in patient inclusion (studies including suspected LGG 28, 31 and studies including more LGG than HGG, 10,32,34 ) high study quality, 10,29,30,35,38 and SUV ratio method. 10,15,32,33,35,38 The covariates' moderating effect on the sensitivity and on the FP rate was evaluated.…”

“…Reasons for exclusion of 196 full-text articles, together with the full search strategy and PRISMA flow diagram is presented inFigure 1. Ultimately, 13 studies10,15,[28][29][30][31][32][33][34][35][36][37][38] were included in the qualitative and quantitative synthesis. Grey literature search identified six registered protocols of not yet published studies aiming to evaluate the DTA of MET PET and two PhD theses.Descriptive summary of data on included studies Included 13 studies comprised 241 patients (89% astrocytomas and 11% oligodendrogliomas).…”

Repurposing drugs as pro‐oxidant redox modifiers to eliminate cancer stem cells and improve the treatment of advanced stage cancers

“…Worldwide, studies with many different cancer types using PET and Cu‐ATSM has established that greater probe uptake is not only associated with oxidative stress, but also with therapeutic resistance, metastatic potential, and poor prognosis (reviewed in Yoshii et al). For example, a study of patients with glioma showed that Cu‐ATSM was a suitable biomarker for predicting the more highly advanced and malignant grades (glioblastoma) and that Cu‐ATSM uptake correlated with high levels of HIF‐1α . Cu‐ATSM was also shown as a selective biomarker for the CD133 + CSCs in colorectal cancer models .…”

“…For example, a study of patients with glioma showed that Cu-ATSM was a suitable biomarker for predicting the more highly advanced and malignant grades (glioblastoma) and that Cu-ATSM uptake correlated with high levels of HIF-1α. 54,55 Cu-ATSM was also shown as a selective biomarker for the CD133 + CSCs in colorectal cancer models. 56,57 As a redox detecting probe, Cu-ATSM has significant selectivity for hypoxic tissues and associated oxidative stress levels in vivo and in vitro because of the redox trapping mechanism and has been compared with results with the 18 F-fluorodeoxyglucose (FDG-PET) probe commonly used for detecting enhanced tumor Glc uptake.…”